4.5 Article

Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study

Journal

NEUROBIOLOGY OF AGING
Volume 31, Issue 8, Pages 1340-1354

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.neurobiolaging.2010.04.030

Keywords

MRI; Alzheimer's disease; Cerebrospinal fluid; Biomarkers; Cortical thickness; Atrophy; Brain tissue volume; ApoE; Mild cognitive impairment; Healthy aging

Funding

  1. National Institutes of Health (NIH)
  2. National Institute of Biomedical Imaging and Bioengineering (NIBIB) [T32 EB001631-05]
  3. Alzheimer's disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  4. National Institute on Aging
  5. National Institute of Biomedical Imaging and Bioengineering
  6. NIH [P30 AG010129, K01 AG030514]

Ask authors/readers for more resources

Previously it was reported that Alzheimer's disease (AD) patients have reduced beta amyloid (A beta(1-42)) 1 and elevated total tau (t-tau) and phosphorylated tau (p-tau(181p)) in the cerebrospinal fluid (CSF), suggesting that these same measures could be used to detect early AD pathology in healthy elderly individuals and those with mild cognitive impairment (MCI). In this study, we tested the hypothesis that there would be an association among rates of regional brain atrophy, the CSF biomarkers A beta(1-42), t-tau, and p-tau(181p) and apolipoprotein E (ApoE) epsilon 4 status, and that the pattern of this association would be diagnosis-specific. Our findings primarily showed that lower CSF A beta(1-42) and higher tau concentrations were associated with increased rates of regional brain tissue loss and the patterns varied across the clinical groups. Taken together, these findings demonstrate that CSF biomarker concentrations are associated with the characteristic patterns of structural brain changes in healthy elderly and mild cognitive impairment subjects that resemble to a large extent the pathology seen in AD. Therefore, the finding of faster progression of brain atrophy in the presence of lower A beta(1-42) levels and higher tau levels supports the hypothesis that CSF A beta(1-42) and tau are measures of early AD pathology. Moreover, the relationship among CSF biomarkers, ApoE epsilon 4 status, and brain atrophy rates are regionally varying, supporting the view that the genetic predisposition of the brain to beta amyloid and tau mediated pathology is regional and disease stage specific. (C) 2010 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available